Archive summary

5 questions about the FDA's fast-track push for psychedelic treatments

The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two studying psilocybin for hard-to-treat depression and one studying methylone, an MDMA-related drug, for PTSD.

Summary of reporting by washingtontimes April 25, 2026 1 min read Markdown